Friday 6 November 2026 Export PRGO’s income statement to Excel — free account

Perrigo Company plc

PRGO Healthcare Drug Manufacturers Specialty & Generic

Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.

Revenue: −5.24%
EPS: −494.6%
Free cash flow: +138.5%
Total debt: −9.62%

Quarter to September 2026, against a year earlier

Dividend growth 10 yrs

15.65 0.06 −0.38%

Follow PRGO

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −7.2×
Dividend yield: 7.41%
F-score: 4/9
Altman Z: −0.08
Beneish M: −3.51
Dividend safety: 16/100

Overview

Perrigo Company plc (PRGO) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Perrigo Company plc (PRGO) trades at a price to free cash flow of 12.4×. Over the past ten years it has ranged from 0.0× (December 2022) to 699× (January 2022); the current reading is higher than 31% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 16.3× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/PRGO/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Perrigo Company plc price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/PRGO/metrics/price-to-free-cash-flow">Perrigo Company plc (PRGO) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	12.6×	2.36%
FY2024	12.3×	(10.26%)
FY2023	13.7×	(30.75%)
FY2022	19.8×	(96.96%)
FY2021	650×	4,915.48%
FY2020	13.0×	(53.36%)
FY2019	27.8×	162.16%
FY2018	10.6×	(42.10%)
FY2017	18.3×	33.19%
FY2016	13.7×	(86.93%)

Period	Price to free cash flow	Change
Sep 2026	11.7×	2.86%
Jun 2026	11.4×	(11.82%)
Mar 2026	12.9×	2.44%
Dec 2025	12.6×	15.56%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 699×

Ten-year median 14.9×

Current reading's percentile 31

Company	Price to free cash flow
ALVO Alvotech compare	n/m
RGC Regencell Bioscience Holdings Limited compare	n/m
HCM HUTCHMED (China) Limited Sponsored ADR compare	n/m
BCRX BioCryst Pharmaceuticals, Inc. compare	5.3×
ANIP ANI Pharmaceuticals, Inc. compare	7.3×
PBH Prestige Consumer Healthcare Inc. compare	9.9×
TRLV Trulieve Cannabis Corp. compare	11.8×
PRGO Perrigo Company plc	12.4×
XERS Xeris Biopharma Holdings, Inc. compare	32.2×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Perrigo Company plc (PRGO) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on PRGO

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on PRGO

Stockrow Weekly